Pilesnil 450 mg+50 mg (Tablet)
Unit Price: ৳ 10.00 (3 x 10: ৳ 300.00)
Strip Price: ৳ 100.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Diosmin hesperidin |
| Company | Chemist laboratories ltd |
Indications
- Acute hemorrhoidal attacks
- Chronic hemorrhoidal disease
- Organic and functional chronic venous insufficiency of the lower limbs with symptoms of heavy legs, pain, nocturnal cramps
Composition
- Each film coated tablet contains Diosmin micronised BP 450 mg
- Each film coated tablet contains Hesperidin micronised INN 50 mg
- Each DS film coated tablet contains Diosmin micronised BP 900 mg
- Each DS film coated tablet contains Hesperidin micronised USP 100 mg
Pharmacology
- Phlebotonic drug and vascular protecting agent
- Reinforces venous tone
- Decreases venous capacitance, distensibility, and emptying time
- Protects microcirculation
- Combats venous inflammation
- Normalizes capillary permeability
- Strengthens capillary resistance
- Improves lymphatic drainage
Dosage
- For acute hemorrhoidal attacks: 3 tablets twice daily for the first 4 days, then 2 tablets twice daily for three days, and if required 1 tablet twice daily as a maintenance dosage
- For chronic hemorrhoids: 1 tablet twice daily
- For chronic venous insufficiency: 1 tablet twice daily initially for seven days, duration may be increased depending on severity
Administration
Tablet should be taken at meal times
Interaction
No evidence of drug incompatibility reported in clinical trials
Contraindications
Contraindicated for anyone having a hypersensitivity to any ingredient in the product
Side Effects
- Routine gastric disorders
- Neurovegetative disorders
- Discontinuation of treatment is not required for these cases
Pregnancy & Lactation
- No teratogenic effect in animals
- No harmful effect reported in human beings
- Breastfeeding not recommended during treatment due to lack of data concerning excretion into breast milk
Precautions & Warnings
- If hemorrhoidal symptoms do not disappear within 15 days, patient should ask doctor for advice
- Diosmin (up to 900 mg/day) has been administered to a small number of breast cancer patients
- No evidence of carcinogenicity or mutagenicity found in animal studies or clinical use in Europe
- Not recommended for patients with a history of cancer
Therapeutic Class
Phlebotonic & Vascular protecting preparation
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children